Cancer Antigen 15-3 (CA15-3) CLIA Kit

Description

​​​​​​​

Background

​​​​​​​​​​​​​​The Cancer Antigen 15-3 (CA15-3) CLIA Kit is designed, developed, and produced for the quantitative measurement of human CA15-3 level in serum samples. The assay utilizes a two-site “sandwich” technique with two antibodies that bind to different epitopes of CA15-3. Assay calibrators, controls, or patient serum samples are added directly to a reaction vessel together with streptavidin coated magnetic particles and biotinylated anti-CA15-3 polyclonal antibody. The magnetic particles capture the biotin antibody as well as an immuno-complex in the form of “magnetic particles–biotin CA15-3 antibody–CA15-3– acridinium ester CA15-3 antibody”. Materials bound to the solid beads are held in a magnetic field while unbound materials are washed away. Then trigger solutions are added to the reaction vessel, and light emission is measured with the ECL100 analyzer. The relative light units (RLU) are proportional to the concentration of a CA15-3 in the sample. The amount of analyte in the sample is determined from a stored, multi-point calibration curve and reported in serum CA15-3 concentration.

Selected Literature

​​​​​​​​​​​​​​1. Croce MV. Detection of circulating mammary mucin (MUC1) and MUC1 immune complexes (MUC1-CIC) in healthy women. The International Journal of Biological Markers, 2001, Vol 16, no 2: 112–120.
2. Duffy MJ. CA 15-3 and related mucins as circulating markers in breast cancer. Ann ClinBiochem, 1999, 36: 579–586.
​​​​​​​3. vonMensdorff-Pouilly S. Human MUC1 mucin: A multifaceted glycoprotein. The International Journal of Biological Markers, 2000, Vol 15, No. 4: 343–356.

For in-vitro diagnostic use.